ILLUMINA INC (ILMN)       213.86  -4.9 (-2.24%)

213.86  -4.9 (-2.24%)

US4523271090 - Common Stock - After market: 213.86 0 (0%)

ILLUMINA INC213.86

NASDAQ:ILMN (12/5/2022, 7:00:03 PM)-4.9 (-2.24%)

After market: 213.86 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Life Sciences Tools & Services
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-03 2022-11-03/amc Earnings (Next) 02-08 2023-02-08
Ins Owners 0.15% Inst Owners 187.88%
Market Cap 33.64B Shares 157.30M
PE 78.34 Fwd PE 55.93
Dividend Yield N/A Analysts 71.2
IPO 06-28 2000-06-28

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ILMN Daily chart

Company Profile

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 9,800 full-time employees. The company went IPO on 2000-06-28. The firm operates through two segments: Core Illumina and GRAIL. Core Illumina products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. GRAIL is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Customers use its platforms to perform whole genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes. The firm's BeadArray technology produces arrays that can perform many assays simultaneously. Customers use its array-based genotyping consumables for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.

Company Info

ILLUMINA INC

5200 Illumina Way

San Diego CALIFORNIA 92122

P: 18582024500.0

CEO: Francis A. deSouza

Employees: 9800

Website: https://www.illumina.com

ILMN News

News Image15 hours ago - Yahoo FinanceUPDATE 1-EU charge sheet tells Illumina to swiftly unwind Grail deal

EU antitrust regulators on Monday proposed measures for U.S. life sciences company Illumina to unwind its acquisition of biotech firm Grail , three months after blocking the deal on concerns that it would hurt competition. Illumina completed the takeover of Grail in August 2021, without securing European Union regulatory approval. The European Commission said in a September veto decision that the company failed to offer adequate remedies to allay its worries and opened a separate case to force Illumina to unravel the deal.

News Image15 hours ago - Wall Street JournalEU Tells Illumina How to Unwind Deal to Buy Cancer-Test Developer Grail

The European Commission said Illumina will have to restore Grail’s independence and return it to the same level that existed before the acquisition.

News Image16 hours ago - Yahoo FinanceIllumina gets EU antitrust charge sheet to unwind Grail acquisition swiftly

EU antitrust regulators on Monday sent a charge sheet to U.S. life sciences company Illumina outlining proposed measures to unwind its acquisition of Grail, three months after they blocked the deal on concerns that it would hurt competition. Illumina completed the deal in August last year without first waiting for EU regulatory approval. The European Commission in its September decision said the company failed to offer adequate remedies to allay its worries.

News Image4 days ago - ChartmillThese S&P500 stocks are gapping in today's session

Let's have a look at the S&P500 gap up and gap down stocks in today's session.

News Image6 days ago - ChartmillTop S&P500 movers in Tuesday's session

Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.

News Image7 days ago - ChartmillTop S&P500 movers in Tuesday's session

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.

ILMN Twits

Here you can normally see the latest stock twits on ILMN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example